1478-3231/asset/LIV_left.gif?v=1&s=85fae709761c931e1b1f055c02ebb481958f0f73)
You have free access to this content
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
Article first published online: 12 MAR 2008
DOI: 10.1111/j.1478-3231.2008.01696.x
© 2008 The Authors. Journal compilation © 2008 Blackwell Munksgaard
Additional Information
How to Cite
Marcellin, P., Lau, G. K. K., Zeuzem, S., Heathcote, E. J., Pockros, P. J., Reddy, K. R., Piratvisuth, T., Farci, P., Chow, W.-C., Jia, J.-D., Paik, W., Wintfeld, N. and Pluck, N. (2008), Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver International, 28: 477–485. doi: 10.1111/j.1478-3231.2008.01696.x
Publication History
- Issue published online: 12 MAR 2008
- Article first published online: 12 MAR 2008
- Received 20 December 2007Accepted 25 December 2007
References
- 1World Health Organization. Hepatitis B and C fact sheets. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 14/02/2006).
- 2, , , Viral hepatitis B. Lancet 2003; 362: 2089–94.
- 3, Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264–70.
- 4, , , et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 420–31.
- 5, , Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–12.
- 6, Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61: 2263–88.
- 7, PEG-IFN alfa-2a plus ribavirin is superior compared to high dose consensus interferon (cIFN) and ribavirin in the treatment of patients with chronic hepatitis C. J Hepatol 2007; 46 (Suppl. 1): S248.
- 8, , , , Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704–8.
- 9, , , et al. Peginterferon alpha-2a (40 kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341–9.
- 10SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
- 11, , , et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 2003; 10: 298–305.
- 12, , , et al. Peginterferon alfa-2a alone, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2602–95.
- 13, , , et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–17.
- 14, , , et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433–8.
- 15, , , et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80.
- 16, , , et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72.
- 17, , , et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
- 18, , , et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99: 1298–305.
- 19, , Chinese SF-36 health survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003; 57: 259–63.
- 20, , , , Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045–53.
- 21, , , et al. HBV 99-01 Study Group. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005; 21: 1163–71.
- 22Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18: 246–52.
- 23, , , et al. HBV 99-01 Study Group. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon alfa-2b therapy. Gut 2005; 54: 1604–9.
- 24, , , Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002; 20: 284–8.
- 25Culture and depression. N Engl J Med 2004; 351: 951–3.
- 26, , , et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491–8.
- 27, , , et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45: 1154–63.
- 28, , , et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845–51.
- 29, , , et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801–8.
- 30, , , , Identification of candidate genes for IFN-mediated depression in HCV patients. J Hepatol 2007; 46 (Suppl. 1): S244.